Summary. Many sequelae associated with endotoxaemicinduced shock result from excessive production of the cytokine mediators, tumour necrosis factor alpha (TNF-a), interleukin 1 (IL-1) and IL-6 from lipopolysaccharide (LPS)-activated monocytes. Protein C (PC)/activated protein C (APC) has potent cytokine-modifying properties and is protective in animal models and human clinical trials of sepsis. The precise mechanism by which this antiinflammatory response is achieved remains unknown; however, the recently described endothelial protein C receptor (EPCR) appears to be essential for this function. The pivotal role that monocytes play in the pathophysiology of septic shock led us to investigate the possible expression of a protein C receptor on the monocyte membrane. We used similarity algorithms to screen human sequence databases for paralogues of the EPCR but found none. However, using reverse transcription±polymerase chain reaction (RT±PCR), we detected an mRNA transcribed in primary human monocytes and THP1 cells that was identical to human EPCR mRNA. We also used immunocytochemical analysis to demonstrate the expression of a protein C receptor on the surface of monocytes encoded by the same gene as EPCR. These results confirm a new member of the protein C pathway involving primary monocytes. Further characterization will be necessary to compare and contrast its biological properties with those of EPCR.
The protein C pathway is a well-established negative regulator of blood coagulation (Esmon, 1992; Esmon et al, 1997) . The pathway is initiated when thrombin binds to the endothelial receptor thrombomodulin, and converts protein C (PC) to the serine protease, activated protein C (APC). The endothelial protein C receptor (EPCR) greatly facilitates protein C activation by presenting the PC substrate to the thrombin:thrombomodulin complex (Stearns-Kurosawa et al, 1996; Fukudome et al, 1998; Taylor et al, 2001) . APC, in collaboration with its cofactor protein S, functions as an anticoagulant by proteolytic cleavage of the procoagulant factors Va and VIIIa. The clinical importance of the PC natural anticoagulant pathway is illustrated by the array of thrombotic phenotypes associated with PC deficiency (Pabinger, 1986) . The protein C pathway also regulates the host response to inflammatory stimuli, as APC has been shown to protect against Escherichia coli-induced septic shock in non-human primates and rodents by reducing cytokine-mediated organ dysfunction (Taylor et al, 1991 (Taylor et al, , 2000 Hancock et al, 1992) . Conversely, inhibition of protein C activation in non-human primates exacerbates the response to sublethal levels of Escherichia coli, resulting in enhanced procoagulant and inflammatory responses (Taylor et al, 1991) .
Over the past decade, a number of case reports and one small series has suggested that PC replacement therapy is associated with a reduction in morbidity and mortality in patients with severe meningococcaemia and purpura fulminans (Rivard et al, 1995; Smith et al, 1997; Rintala et al, 1998; Smith & White, 1999) . In the past year, further evidence to support the dual functional property (anticoagulant and anti-inflammatory) of PC/APC has emerged from two published clinical studies (White et al, 2000a; Bernard et al, 2001) . The first was an open-label prospective study assessing the efficacy of PC replacement therapy in patients with severe meningococcal septicaemia, purpura fulminans and multiorgan failure, and its use was associated with a significant reduction in predicted morbidity and mortality (White et al, 2000a) . The second was the first randomized trial to use this anticoagulant in patients with severe sepsis and again the study showed a significant reduction in mortality associated with the use of APC despite an increase in haemorrhagic events (Bernard et al, 2001 ).
The precise mechanism by which the protein C pathway modulates the inflammatory response has not been fully elucidated, although protein C binding to the EPCR is a key feature. EPCR is a type 1 transmembrane protein, with sequence homology to members of the major histocompatibility class 1/CD1 family of molecules involved in the immune response (Fukudome & Esmon, 1994 . The involvement of the EPCR in inflammatory processes has been demonstrated in vitro, in which EPCR expression is downregulated by tumour necrosis factor alpha (TNF-a) (Fukudome & Esmon, 1994) . In vivo studies have also shown that EPCR expression is upregulated by lipopolysaccharide (LPS), a response mediated via thrombin (Gu et al, 2000) . Additionally, in baboons, inhibition of protein C±EPCR interaction results in an increased inflammatory response following Escherichia coli infusion (Taylor et al, 2000) .
Many of the sequelae associated with endotoxaemicinduced shock result from excessive production of the cytokine mediators, TNF-a, interleukin 1 beta (IL-1b) and IL-6 from LPS-activated monocytes. In vitro, APC downregulates endotoxin-induced production of TNF-a and IL-6 (Taylor et al, 1987; Grey et al, 1994; Murakami et al, 1996; White et al, 2000b) , as well as inhibiting the nuclear translocation of nuclear factor kB (NF-kB) (White et al, 2000b) , a critical transcription factor in LPS-induced proinflammatory cytokine production in monocytic cells (Mackman, 2000) . APC also inhibits TNF-a production in rats given LPS, leading to reduced neutrophil-induced pulmonary vascular injury (Murakami et al, 1996 (Murakami et al, , 1997 . Suppression of monocyte cytokine production is not a generalized toxic effect, as monocyte responses associated with adhesion, phagocytosis and killing of bacteria are maintained. APC operates in the opposite manner to LPS, by promoting the migration of monocytic cells to a site of infection, primarily by blocking downregulation of monocyte surface receptors for LPS (Grey et al, 1994) . These beneficial immunomodulatory effects of PC/APC on activated monocytes are probably mediated through a receptor analogous to EPCR. Previous studies have demonstrated that EPCR expression is not restricted to the endothelium. It has, for example, been detected in a number of cancer cell lines including those derived from monoblastic leukaemia (U937), glioblastoma (U87, T98G), osteosarcaoma (HOS) and erythroleukaemia (HEL, K562) (Fukudome & Esmon, 1994; Tsuneyoshi et al, 2001) . EPCR has been shown to enhance PC activation on U87, T98G and U937 cells, suggesting that it may contribute towards coagulation disorders observed in cancer patients (Tsuneyoshi et al, 2001) . In addition, a previous study has demonstrated that APC binds to primary monocytes in a time-dependent, saturatable and reversible manner, and that binding increases following LPS-induced monocyte activation. There appear to be approximately 200 000 high affinity binding sites per monocyte and concurrent biochemical studies indicated that an associated 50±55 kDa monocyte membrane protein may function as an APC-specific receptor on these cells (Hancock et al, 1995) .
Given the clinical significance of PC/APC therapy in favourably modulating the pro-coagulant and inflammatory response in patients with sepsis, it is important to elucidate the cellular and molecular targets by which this is achieved. In this study we have identified, for the first time at both an mRNA and protein level, a protein C receptor expressed on the surface of human monocytes. These results confirm a new member of the protein C pathway involving primary monocytes and further characterization will be necessary to compare and contrast its biological properties with that of EPCR.
MATERIALS AND METHODS
All reagents were from Sigma (St Louis, MI, USA) unless otherwise stated.
Tissue culture. Epithelial ECV304 cells, Jurkat human leukaemic T cells and human monocytic THP1 cells were obtained from the European Collection of Cell Cultures (Salisbury, UK). ECV304 cells were maintained in 199 medium supplemented with 10% fetal calf serum (FCS), penicillin (50 units/ml), streptomycin (50 mg/ml) (all Gibco BRL, UK) and 2 mmol/l l-glutamine. THP1 and Jurkat cells were maintained in RPMI-1640 medium (Gibco BRL) containing 10% FCS, penicillin (50 units/ml), streptomycin (50 mg/ml) and 2 mmol/l l-glutamine. All cell lines were maintained at 378C in a 5% CO 2 environment. Primary human monocyte isolation. Peripheral blood mononuclear cells (PBMC) were isolated from venous blood drawn from normal healthy volunteers, by centrifugation on Ficoll-Hypaque density gradients (English & Andersen, 1974) . Monocyte purification was carried out by depletion of non-monocytes using a monocyte isolation kit (Miltenyi Biotec, Bergish Gladbach, Germany) according to the manufacturer's instructions. Anti-CD61 microbeads (Miltenyi Biotech) were also used for removal of platelets. Monocytes were isolated by passing the PBMC through a magnetic cell separation system (MACS; Miltenyi Biotec) with a type LS 1 column. More than 95% of the cells were judged to be monocytes by morphology and positive staining for CD14 in a flow cytometric analysis.
RNA preparation and reverse transcription±polymerase chain reaction (RT±PCR). Total RNA was isolated from cells using the Purescriptw RNA isolation kit (Gentra systems, Minneapolis, MN, USA) according to the manufacturer's instructions, then DNase-treated using RQ1 Rnase-Free Dnase (Promega, Madison, WI, USA), again following the manufacturer's guidelines. Dnase-treated total RNA (2 mg) was used for cDNA synthesis using AMV RT and a poly dTTP primer (both Promega). Amplification of cDNA samples by PCR was performed in a PTC 2000 thermal cycler (MJ Research, USA) using Taq DNA polymerase and standard methods (Simmonds et al, 1990) . cDNA produced from the RT reaction was used as a template. All amplifications were primed by pairs of chemically synthesized EPCR-specific 17±22-mer oligonucleotides (Table I, Fig 1) , designed using the published EPCR cDNA sequence (Fukudome & Esmon, 1994) , which span exon boundaries to control for DNA contamination. cDNA products were separated by electrophoresis on 3% agarose gels in Trisborate-EDTA (TBE) buffer in the presence of 1 mg/ml ethidium bromide. PCR products were purified using the High Pure PCR Product Purification Kit (Roche, Mannheim, Germany) according to the manufacturer's instructions and cDNA concentration was determined spectrophotometrically.
Sequence analysis. The nucleotide sequence was determined by MWG Biotech AG (Ebersberg, Germany) using an ABI sequencer with Big Dye chemistry (Applied Biosystems, Foster City, CA, USA). The reactions were primed using the antisense oligonuceotides used in the amplification reaction (EPCR 1±3C and D as shown in Table I ). All DNA sequences were determined in both directions.
Computer analysis. Nucleotide database searching used the Electronic PCR (Schuler, 1997) and blast version 2´0 (Altschul et al, 1997) [National Centre for Biotechnology Information (NCBI), National Institutes of Health, Bethesda, MD, USA] programs with the GenBank and UniGene databases.
Immunocytochemistry. The staining procedure was carried out on both THP1 cells and primary human monocytes. Cells (2 Â 10 5 ) were incubated in phosphate-buffered saline (PBS) containing 1% bovine serum albumin (BSA), 0´15% sodium azide (binding buffer) and rabbit serum (7´5% for THP1 cells, 15% for primary monocytes) for 15 min at 48C to block Fc receptors. They were incubated at 48C for a further 20 min with an EPCR-specific monoclonal antibody (mAb), RCR-379 (1 mg/ml). Cells were washed twice and resuspended in binding buffer containing fluorescein isothiocyanate (FITC)-conjugated rabbit anti-rat IgG F(ab H ) 2 fragments (1 mg/ml) (Jackon ImmunoResearch,West Grove, PA, USA) and R-phycoerythrin (RPE)-conjugated mouse anti-human CD14-specific mAb (6 mg/ml) (DAKO, Glostrup, Denmark). Cells were washed as previously and resuspended in binding buffer containing bis Benzimide (2´5 mg/ml). Cells were washed once more and fixed in 2% paraformaldehyde. As negative controls, Jurkat cells were also stained and monocyte negative controls were stained by omission of the primary antibodies. Cells were viewed by using a Leica photomicroscope (Leica Microscopy Systems, Heerbrugg, Switzerland) and Leica qfluoro software and processed using Adobe PHOTOSHOP 5´0. Equal exposure times were used to photograph cells with specific and negative control staining.
RESULTS

Database analysis
Homology searching of web-based sequence databases was performed to investigate the possibility that a monocytespecific protein C receptor gene exists, distinct from the EPCR gene. Preliminary searches of the non-redundant and HTGS nucleotide database maintained by the NCBI (GenBank) for homologues of the EPCR gene (GenBank accession number AF106202) using blastn version 2.0 yielded no significant matches other than EPCR itself, while TBLASTX also yielded the CCD41 protein as a significant match. CCD41 is a centrosomal protein encoded by the EPCR gene. To extend the investigation, the UniGene database was also searched using the EPCR gene 3 H untranslated region. No additional protein C receptor sequence was detected in the UniGene cluster identified using the EPCR sequence. Finally, H and 3 H untranslated regions. PCR products 1 (328 bp), 2 (450 bp) and 3 (476 bp) are shown below the gene. Primers were designed to amplify cDNA from two different exons, thus ensuring specific amplification of cDNA and not potentially contaminating genomic DNA. Therefore, dotted lines represent intron regions not amplified by the PCR strategy. the electronic PCR program was used to search for analogous sequences containing EPCR-specific sequencetagged sites. Again, no sequence was detected that was likely to encode a second protein C receptor.
Sequence data RT±PCR was employed to detect possible EPCR gene expression in monocytes. Three overlapping cDNA fragments of 328, 450 and 476 bp were generated by RT±PCR using mRNA from both THP1 cells and primary monocytes (Fig 1) . mRNA specificity was confirmed using a no reverse transcriptase control for each RT±PCR reaction. The nucleotide sequence was determined for each fragment. THP1-derived fragments were then overlapped to form a 776-bp contig (Fig 2A) , while those derived from primary monocytes were overlapped to form a 750-bp contig (Fig 2B) . The sequence of these contigs is identical to that of EPCR cDNA, representing over 96% of the coding sequence of the EPCR gene. The ECV304 cell line was chosen as a positive control for EPCR expression in RT±PCR analysis, as it displays many endothelial cell characteristics including TM expression. Using the same RT±PCR reaction conditions, identical cDNA was amplified using RNA isolated from ECV304 cells but could not be amplified from RNA extracted from Jurkat cells.
Immunocytochemistry
To verify translation of EPCR mRNA detected by RT±PCR and illustrate cell surface expression of the resulting protein, we utilized a monoclonal antibody, RCR-379, prepared against the human EPCR protein. RCR-379 bound uniformly to the membrane surface of primary human monocytes (Fig 3) as shown by fluorescent microscopy. A similar binding pattern was detected on the membrane surface of THP1 cells (data not shown). No monocyte protein C receptor-associated fluorescence was detected in the control EPCR-negative Jurkat cells or in THP1 cells stained by omission of the primary antibody. A low level of non-specific fluorescence contributed by residual Fc-receptor-mediated binding was detected in less than 10% of primary human monocytes stained by omission of the primary antibody. Monocyte specificity of the staining procedure was determined for each sample with the use of RPE-labelled CD14-specific mAb.
DISCUSSION
The aim of this study was to verify the presence of a receptor on the monocyte membrane surface that is likely to facilitate activation of protein C, similar to the manner in which the EPCR augments PC activation on endothelial cells. To search for a possible gene encoding a monocyte protein C receptor, we initially searched the NCBI sequence databases for sequences homologous to the EPCR gene. No homologues of human EPCR were found in GenBank (unfinished and finished human genomic sequences) or UniGene. Thus, the protein C receptor detected on monocytes probably results from expression of the same gene that encodes the EPCR.
To detect possible expression of the EPCR gene in monocytes, primers designed using the EPCR sequence as a template were used in RT±PCR reactions to successfully amplify mRNA from both THP1 cells and primary monocytes. Sequencing of the resulting cDNA revealed it to be identical to the EPCR mRNA. Over 96% of the EPCR coding sequence was sequenced. This sequence codes for the complete extracellular region (exons II, III and IV), the transmembrane domain and cytoplasmic tail (exon IV) and part of the signal peptide (exon I) of the monocyte protein C receptor (Hayashi et al, 1999; Simmonds & Lane, 1999) . Previous work carried out to detect EPCR mRNA expression in THP1 cells using Northern blot analysis has been unsuccessful, although EPCR mRNA has been detected in the U937 monoblastic cell line using this method (Fukudome & Esmon, 1994; Tsuneyoshi et al, 2001) . Apart from variation in cell culture conditions, heterogeneity of THP1 cells from various sources is the most likely explanation for this apparent differential expression of the EPCR gene. The high sensitivity of nested PCR may also detect low levels of mRNA, indiscernible by Northern blotting.
Although monocytes express EPCR gene mRNA, it is known that functionally distinct proteins may arise from one gene following post-translational modification. The EPCR gene was recently shown to encode a modified protein (CCD41) which was predominantly detected in centrosomes and perinuclear vesicles, and which was speculated to function in cell cycle control (Rothbarth et al, 1993 (Rothbarth et al, , 1999 . CCD41 arises following deletion of the signal sequence from the precursor protein and is targeted to the centrosome, whereas the unmodified protein, EPCR, is targeted to the plasma membrane. In Ehrlich ascites tumour (EAT) cells, the signal sequence of relatively few precursor protein molecules is cleaved, resulting in no membrane protein expression. However, inability to cleave the signal peptide of higher levels of precursor protein results in membrane targeting of the full-length polypeptide (Rothbarth et al, 1999) . It is important to consider that tumour cell lines such as EAT may not always mirror the fundamental in vivo functions of the protein C pathway. For example, although the EPCR is primarily found in the endothelium, low levels have also been detected in several cell lines derived from cancer (Fukudome & Esmon, 1995; Tsuneyoshi et al, 2001) . Thrombomodulin expression has also been detected in a tumour cell line but is absent from normal cells from which the tumour line originated (Muruyama & Majerus, 1985) . Thus, caution must be taken in interpretation of CCD41/ EPCR expression levels in the EAT cell line. A distinct CCD41 function has not been demonstrated. It is possible that it is simply a negative regulatory artefact of the EPCR protein.
On the endothelium, the efficiency of PC activation appears to be determined by EPCR surface density, as receptorinduced enhancement of PC activation is not saturated even at EPCR to thrombomodulin ratios of 14:1 (Xu et al, 1999) . Thus, it is likely that surface receptor levels are modulated at an expression level or by subcellular localization. CCD41 may simply be a result of the latter regulatory event. Consequently, EPCR gene mRNA detected in monocytes may be the result of either CCD41 transcription or subcellular EPCR expression. Likewise, because mRNA detection was not quantitative, it could result from basal level expression of the EPCR gene, which is physiologically irrelevant. To discount both these possibilities, expression of a functional protein C receptor in monocytes must be confirmed at a protein level.
Monocyte membrane expression of a protein C receptor was conclusively established using RCR-379, a mAb raised against EPCR that was indirectly labelled with the fluorochrome FITC and visualized by fluorescence microscopy. Both THP1 cells and primary monocytes expressed a membrane protein C receptor as demonstrated by RCR-379 cross-reactivity. Antibody specificity was confirmed by lack of cross-reactivity with Jurkat negative control cells. Negatively stained control THP1 and primary monocyte cells verified RCR-379 specificity of the FITC-labelled secondary antibody.
There is considerable evidence to suggest an important physiological role for the protein C receptor expressed on monocytes. The level of PC activation via the monocyteassociated thrombin:thrombomodulin complex is unlikely to explain the emerging significance of PC in facilitating the anticoagulant and anti-inflammatory action of these cells. Binding of PC to a receptor on the monocyte surface may facilitate this action in a similar manner to the EPCRmediated augmentation of APC function on the endothelium. However, a previous study has shown that the protein C receptor on monocyes binds APC but not PC or enzymatically inactive APC (Hancock et al, 1995) . Thus, further investigation is required to quantify both expression levels and the extent of the biological effect of a protein C receptor on the monocyte surface.
Severe sepsis and septic shock remain important clinical problems and, until very recently, the use of novel biological compounds as adjunct therapy have failed. We now know that activated protein C not only controls pro-coagulation in the microcirculation but has potent cytokine-modifying properties, and these two properties clearly contribute to the reduced morbidity and mortality rates seen in animal models and human clinical trials of sepsis when this biological therapeutic is used. Identification of the key components in the procoagulant and inflammatory process of sepsis in the monocyte is crucial for a better understanding of the pathophysiology of this disease. Characterization of the protein C receptor expressed on the monocyte surface will significantly contribute to such an understanding and will hopefully encourage future clinical investigations into different biological interventions that will ultimately lead to the availability of a number of effective antisepsis therapeutics.
